Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.727
Index Copernicus  – 166.39
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 6, November-December, p. 1255–1263

doi: 10.17219/acem/65781

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Assessment of Selected ROTEM Parameters, Kinetics of Fibrinogen Polymerization and Plasmin Amidolytic Activity in Patients with Congenital Fibrinogen Defects

Jacek Treliński1,2,A,B,C,D,E,F, Katarzyna Pachniewska2,B,C,E,F, Justyna Matczak3,B,C,F, Paweł Nowak3,B,F, Marta Robak2,B,C,E,F, Krzysztof Chojnowski2,A,B,C,D,E,F

1 Department of Hematology, Medical University of Łódź, Poland

2 Department of Hemostasis, Medical University of Łódź, Poland

3 Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Łódź, Poland


Background. Congenital fibrinogen disorders (CFD) are rare fibrinogen deficiencies which may be quantitative or functional. The clinical course of hypofibrinogenemia (hypoFI) or dysfibrinogenemia (dysFI) is unpredictable and cannot be determined by the application of standard hemostasis tests.
Objectives. The main aim of this study was to assess ROTEM parameters in CFD patients.
Material and Methods. Nine patients with CFD were studied. The fibrinogen concentration was measured functionally and antigenically. EXTEM, INTEM, FIBTEM and APTEM tests were used to measure selected ROTEM parameters, including maximum clot firmness (MCF). Fibrin plasma polymerization, clot lysis and plasmin amidolytic activity were determined by spectrophotometric methods.
Results. Incorporating the antigenic, ELISA method, to the diagnostic workup allowed the initial diagnosis to be switched from hypoFI to dysFI in 3/7 patients. MCF readings (the most important parameter describing fibrin polymerization capacity) were significantly lower in patients than in controls according to all ROTEM tests. Cases with hypoFI demonstrated markedly lower readings of MCF according to all ROTEM tests than cases with dysFI. All patients demonstrated disturbances of fibrin polymerization process assessed by turbidimetry. In contrast, no marked differences were identified between studied groups in reference to plasmin amidolytic activity.
Conclusion. Our data suggests that ROTEM and fibrin plasma polymerization according to the turbidimetric method have a high sensitivity towards detection of different CFD. Although ROTEM MCF assessment may help discriminate patients with hypoor dysfibrinogenemia, this finding has to be confirmed on larger groups of patients.

Key words

ROTEM, congenital fibrinogen disorders, fibrin plasma polymerization by turbidimetric method

References (33)

  1. Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P: Dysfibrinogenemia: From molecular anomalies to clinical manifestations and management. J Thromb Haemost 2015, 13, 909–919.
  2. De Moerloose P, Casini A, Neerman-Arbez M: Congenital fibrinogen disorders: An update. Semin Thromb Hemost 2013, 39, 585–595.
  3. Mannucci PM, Duga S, Peyvandi F: Recessively inherited coagulation disorders. Blood 2004, 104, 1243–1252.
  4. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM: Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999, 107, 204–206.
  5. Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, Mumford AD: Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 2013, 160, 220–227.
  6. Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E, Gautier P, Biron C, Neerman-Arbez M, de Moerloose P: Natural history of patients with congenital dysfibrinogenemia. Blood 2015, 125, 553–561.
  7. Miesbach W, Schenk J, Alesci S, Lindhoff-Last E: Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res 2010, 126, 428–433.
  8. Peyvandi F: Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res 2012, 130, 7–11.
  9. Brazzel C: Thromboelastography-guided transfusion therapy in the trauma patient. AANA J 2013, 81, 127–132.
  10. Lancé MD: A general review of major global coagulation assays:thrombelastography, thrombin generation test and clot waveform analysis. Thromb J 2015, 13, 1.
  11. Hunt H, Stanworth S, Curry N, Woolley T, Cooper C, Ukoumunne O, Zhelev Z, Hyde C: Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev 2015, 16, 2:CD010438. DOI: 10.1002/14651858.CD010438.pub2.
  12. Desborough MJ, Jairath V: Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy. Hepatology 2015, 6, DOI: 10.1002/hep.28336.
  13. Levi M, Hunt BJ: A critical appraisal of point-of-care coagulation testing in critically ill patients. J Thromb Haemost 2015, 13, 1960–1967.
  14. Treliński J, Misiewicz M, Robak M, Smolewski P, Chojnowski K: Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis. Thromb Res 2014, 133, 667–670.
  15. Treliński J, Okońska M, Robak M, Chojnowski K: Assessment of rotation thromboelastometry (ROTEM) parameters in patients with essential thrombocythemia at diagnosis and after hydroxyurea therapy. Blood Coagul Fibrin (in press).
  16. Zhou J, Xin Y, Ding Q, Jiang L, Chen Y, Dai J, Lu Y, Wu X, Liang Q, Wang H, Wang X: Thromboelastographic predicts risks of obstetric complication occurrence in (hypo)dysfibrinogenemia patients under non-pregnant state. Clin Exp Pharmacol Physiol 2015, 28. DOI: 10.1111/1440-1681.12509.
  17. Zhou J, Ding Q, Chen Y, Ouyang Q, Jiang L, Dai J, Lu Y, Wu X, Liang Q, Wang H, Wang X: Clinical features and molecular basis of 102 Chinese patients with congenital dysfibrinogenemia. Blood Cells Mol Dis 2015, 55, 308–315.
  18. Galanakis DK, Neerman-Arbez M, Brennan S, Rafailovich M, Hyder L, Travlou O, Papadakis E, MancoJohnson MJ, Henschen A, Scharrer I: Thromboelastographic phenotypes of fibrinogen and its variants: clinical and non-clinical implications. Thromb Res 2014, 133, 1115–1123.
  19. Luddington RJ: Thrombelastography/thromboelastometry. Clin Lab Haematol 2005, 27, 81–90.
  20. Lang T, Bauters A, Braun SL, Pötzsch B, von Pape KW, Kolde HJ: Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005, 16, 301–310.
  21. Lang T, von Depka M: Possibilities and limitations of thrombelastometry/-graphy. Hamostaseologie 2006, 26, 20–29.
  22. Kostka B, Para J, Sikora J: A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening. Blood Coagulation Fibrinol 2007, 18, 611–618.
  23. Soria J, Soria C, Samama M: Plasminogen determination using a chromogenic tripeptidic substrate. Pathol Biol 1976, 24, 725–779.
  24. Takada A, Shizume K, Cho M, Takada Y: Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase. Thromb Res 1987, 45, 371–381.
  25. Friberger P: Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. Scand J Clin Lab Invest 1982, 162, 1–298.
  26. Krammer B, Anders O, Nagel HR, Burstein C, Steiner M: Screening of dysfibrinogenaemia using the fibrinogen function versus antigen concentration ratio. Thromb Res 1994, 76, 577–579.
  27. Verhovsek M, Moffat KA, Hayward CP: Laboratory testing for fibrinogen abnormalities. Am J Hematol 2008, 83, 928–931.
  28. Solomon C, Rahe-Meyer N, Schöchl H, Ranucci M, Görlinger K: Effect of haematocrit on fibrin-based clot firmness in the FIBTEM test. Blood Transfus 2013, 11, 412–418.
  29. Whiting D, DiNardo JA: TEG and ROTEM: Technology and clinical applications. Am J Hematol 2014, 89, 228–232.
  30. Sankarankutty A, Nascimento B, Teodoro da Luz L, Rizoli S: TEG ® and ROTEM ® in trauma: Similar test but different results? World J Emerg Surg 2012, 7, S3.
  31. Da Luz LT, Nascimento B, Rizoli S: Thrombelastography (TEG ® ): practical considerations on its clinical use in trauma resuscitation. Scand J Trauma Resusc Emerg Med 2013, 21, 29.
  32. Kalina U, Stöhr HA, Bickhard H, Knaub S, Siboni SM, Mannucci PM, Peyvandi F: Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis 2008, 19, 777–783.
  33. Lord ST: Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol 2011, 31, 494–499.